Limits...
Safety and efficacy of switching from dorzolamide 1.0%/timolol maleate 0.5% eye drops to brinzolamide 1.0%/timolol maleate 0.5% eye drops.

Inoue K, Shiokawa M, Ishida K, Tomita G - Clin Ophthalmol (2015)

Bottom Line: A total of 33.3% and 27.3% of patients preferred DTFC and BTFC, respectively.Switching from DTFC to BTFC was well tolerated and did not result in IOP changes or a decreased patient adherence.When glaucoma patients complain of stinging with DTFC administration, switching to BTFC is an acceptable treatment option.

View Article: PubMed Central - PubMed

Affiliation: Inouye Eye Hospital, Tokyo, Japan.

ABSTRACT

Purpose: To evaluate the safety and efficacy of switching from dorzolamide 1.0%/timolol maleate 0.5% fixed-combination (DTFC) eye drops to brinzolamide 1.0%/timolol maleate 0.5% fixed-combination (BTFC) eye drops in patients with primary open-angle glaucoma or ocular hypertension.

Methods: A total of 35 eyes of 35 patients with primary open-angle glaucoma or ocular hypertension using DTFC eye drops were included. Participants discontinued DTFC drops and immediately began using BTFC drops. All other eye drops currently being used were continued. Intraocular pressure (IOP) 1 and 3 months after switching medications was compared with baseline IOP. One month after switching medications, participant preference and adherence were evaluated. Adverse reactions were monitored at each study visit.

Results: The IOP was 17.9±2.6 mmHg at baseline and 18.3±4.1 mmHg and 17.8±3.4 mmHg 1 month and 3 months after switching medications, respectively (P=0.633). The frequency of missing a dose was not different before (6.1%) and after (6.1%) switching to BTFC. Significantly fewer participants reported stinging after switching to BTFC (15.2%) than while using DTFC (51.5%, P,0.01). Blurred vision was reported with the same frequency before (39.4%) and after (42.4%) switching to BTFC. A total of 33.3% and 27.3% of patients preferred DTFC and BTFC, respectively. Several patients withdrew from the study because of discomfort (n=2, 5.7%), discharge (n=1, 2.9%), dizziness (n=1, 2.9%), or increased IOP (n=2, 5.7%).

Conclusion: Switching from DTFC to BTFC was well tolerated and did not result in IOP changes or a decreased patient adherence. When glaucoma patients complain of stinging with DTFC administration, switching to BTFC is an acceptable treatment option.

No MeSH data available.


Related in: MedlinePlus

Patient preferences for each medication examined.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4401356&req=5

f3-opth-9-619: Patient preferences for each medication examined.

Mentions: A total of 9 (27.3%) participants preferred to use BTFC drops, 11 (33.3%) participants preferred to use DTFC drops, and 13 (39.4%) participants expressed no preference (Figure 3). Subjects preferred BTFC drops because they had less stinging (n=5 subjects) and better IOP reduction (n=5 subjects). Subjects preferred DTFC drops because they had less blurred vision (n=7 subjects), less stinging (n=2 subjects), and less discomfort (n=2 subjects).


Safety and efficacy of switching from dorzolamide 1.0%/timolol maleate 0.5% eye drops to brinzolamide 1.0%/timolol maleate 0.5% eye drops.

Inoue K, Shiokawa M, Ishida K, Tomita G - Clin Ophthalmol (2015)

Patient preferences for each medication examined.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4401356&req=5

f3-opth-9-619: Patient preferences for each medication examined.
Mentions: A total of 9 (27.3%) participants preferred to use BTFC drops, 11 (33.3%) participants preferred to use DTFC drops, and 13 (39.4%) participants expressed no preference (Figure 3). Subjects preferred BTFC drops because they had less stinging (n=5 subjects) and better IOP reduction (n=5 subjects). Subjects preferred DTFC drops because they had less blurred vision (n=7 subjects), less stinging (n=2 subjects), and less discomfort (n=2 subjects).

Bottom Line: A total of 33.3% and 27.3% of patients preferred DTFC and BTFC, respectively.Switching from DTFC to BTFC was well tolerated and did not result in IOP changes or a decreased patient adherence.When glaucoma patients complain of stinging with DTFC administration, switching to BTFC is an acceptable treatment option.

View Article: PubMed Central - PubMed

Affiliation: Inouye Eye Hospital, Tokyo, Japan.

ABSTRACT

Purpose: To evaluate the safety and efficacy of switching from dorzolamide 1.0%/timolol maleate 0.5% fixed-combination (DTFC) eye drops to brinzolamide 1.0%/timolol maleate 0.5% fixed-combination (BTFC) eye drops in patients with primary open-angle glaucoma or ocular hypertension.

Methods: A total of 35 eyes of 35 patients with primary open-angle glaucoma or ocular hypertension using DTFC eye drops were included. Participants discontinued DTFC drops and immediately began using BTFC drops. All other eye drops currently being used were continued. Intraocular pressure (IOP) 1 and 3 months after switching medications was compared with baseline IOP. One month after switching medications, participant preference and adherence were evaluated. Adverse reactions were monitored at each study visit.

Results: The IOP was 17.9±2.6 mmHg at baseline and 18.3±4.1 mmHg and 17.8±3.4 mmHg 1 month and 3 months after switching medications, respectively (P=0.633). The frequency of missing a dose was not different before (6.1%) and after (6.1%) switching to BTFC. Significantly fewer participants reported stinging after switching to BTFC (15.2%) than while using DTFC (51.5%, P,0.01). Blurred vision was reported with the same frequency before (39.4%) and after (42.4%) switching to BTFC. A total of 33.3% and 27.3% of patients preferred DTFC and BTFC, respectively. Several patients withdrew from the study because of discomfort (n=2, 5.7%), discharge (n=1, 2.9%), dizziness (n=1, 2.9%), or increased IOP (n=2, 5.7%).

Conclusion: Switching from DTFC to BTFC was well tolerated and did not result in IOP changes or a decreased patient adherence. When glaucoma patients complain of stinging with DTFC administration, switching to BTFC is an acceptable treatment option.

No MeSH data available.


Related in: MedlinePlus